Incyte Corporation Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (43)

Latest Posts

About This Stock More About This Stock
Top Biotech Bets From The Baker Brothers
Article By: MoneyShow.com
Wednesday, September 28, 2022 5:00 AM EST
Baker Bros. Advisors is a private hedge fund based. Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings.
In this article: ACAD, BMRN, BGNE, INCY
Read
Insights On Incyte Corporation
Article By: MoneyShow.com
Saturday, June 4, 2022 6:03 PM EST
In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million beating the consensus estimate of $11 million.
In this article: INCY
Read
For Hedge Funds, This Is The Worst 6 Months Since The Financial Crisis: Here's Why
Article By: Tyler Durden
Saturday, August 21, 2021 10:46 PM EST
The core issues behind recent (and continuing) hedge fund under- performance: concentration, crowding and turnover.
In this article: INCY, BRK-B, MA, MCHI, TDG, V, WFC, BIDU, AAPL, AMZN, EXPE, MSFT, BABA, FB, GOOGL, JD, PYPL, WLTW, UAA, SE, BILI, DIDI
Read
3 Promising Oncology Stocks To Consider Adding To Your Portfolio
Article By: StockNews
Monday, June 14, 2021 12:31 AM EST
With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.
In this article: AZN, INCY, AMGN Also: SPY, CNCR
Read
Incyte Q2 Earnings And Revenues Beat Estimates
Article By: Zacks Investment Research
Tuesday, August 4, 2020 9:55 AM EST
Incyte came out with quarterly earnings of $1.24 per share.
In this article: INCY
Read

Latest Tweets for $INCY

No tweets yet!

PARTNER HEADLINES